8-K
false 0001708493 0001708493 2021-12-11 2021-12-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2021

 

 

Harpoon Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-38800   47-3458693

(State or Other Jurisdiction

of Incorporation)

  (Commission
File Number)
 

(IRS Employer

Identification No.)

 

131 Oyster Point Blvd, Suite 300

South San Francisco, California

  94080
(Address of Principal Executive Offices)   (Zip Code)

(650) 443-7400

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, par value $0.0001 per share   HARP   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


Item 8.01 Other Events.

On December 11, 2021, Harpoon Therapeutics, Inc. (the “Company”) issued a press release regarding the announcement of interim clinical data from its ongoing Phase 1/2 clinical study and new preclinical results for BCMA-targeting TriTAC® HPN217 at the 63rd American Society for Hematology Annual Meeting and Exposition. On December 13, 2021, the Company issued a press release announcing clinical progress across all four of the Company’s TriTAC® pipeline development programs, and the Company posted a presentation (the “Presentation”) regarding these updates. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2 and a copy of the Presentation is attached hereto as Exhibit 99.3. The exhibits are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.    Description
99.1    Press Release, dated December 11, 2021.
99.2    Press Release, dated December 13, 2021.
99.3    Clinical Pipeline Update Presentation, dated December 13, 2021.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HARPOON THERAPEUTICS, INC.
By:  

/s/ Julie Eastland

 

Julie Eastland

President and Chief Executive Officer

Dated: December 13, 2021

EX-99.1

Exhibit 99.1

 

LOGO

FOR IMMEDIATE RELEASE

Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition

Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma

Tolerable safety profile with cytokine release syndrome (all Grade 1 or 2) observed in 9 of 37 patients (24%)

Patient enrollment and dose escalation is ongoing to define the RP2D and MTD

Management to host webcast and conference call to review the HPN217 data presented at ASH and provide a pipeline update on Monday, December 13, 2021 at time 4:30 p.m. ET / 1:30 p.m. PT

SOUTH SAN FRANCISCO, Calif., December 11, 2021—Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a poster with interim data from the ongoing dose-escalation portion of the Phase1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma (R/R MM) at the 63rd American Society for Hematology (ASH) Annual Meeting and Exposition. HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells.

As of November 10, 2021, the data cutoff date for the interim clinical data presentation, 37 patients have been dosed across 10 cohorts at fixed doses of 5 to 2860 µg/week and in step dosing cohorts up to 3240 µg/week administered as an intravenous infusion. These interim data demonstrated:

 

   

HPN217 is generally well tolerated with one dose limiting toxicity (DLT) reported of Grade 4 AST elevation that resolved, MTD has not been reached

 

   

HPN217 is clinically active at higher dose levels with clinical benefit, disease control rate (DCR) of 88%, demonstrated in 7 of 8 disease evaluable patients in the 2150 µg/week cohort

 

   

2 stringent complete responses (SCRs) have been observed, one in each of the higher dose 2150 and 2860 µg/week cohorts

 

   

Transient and manageable cytokine release syndrome (CRS) reported in 9 of 37 patients (24%) were all Grade 1 or 2

 

   

Introduction of step dose regimens has allowed for the administration of higher target doses, currently at 3240 µg/week

“These encouraging data for HPN217 demonstrate robust clinical activity at higher doses, strong target engagement, and a manageable safety profile in this heavily refractory patient population,” said Natalie Sacks, M.D., Chief Medical Officer of Harpoon Therapeutics. “Dose escalation is ongoing to determine the RP2D for advancement into the expansion phase of the trial.”

Interim Results from the Ongoing HPN217 Phase 1/2 Trial Presented at ASH

This Phase 1/2 trial is a multicenter, open-label study designed to evaluate safety, tolerability, pharmacokinetics and clinical activity in patients with R/R MM who have had at least three prior systemic treatments including a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody. The


initial ongoing phase of the trial is dose escalation, with the goal of determining a recommended dose for the expansion phase. The escalation phase began with single patient cohorts and transitioned to a 3+3 design when Grade 2 toxicity was observed. HPN217 is being administered to patients once weekly by intravenous infusion and the primary outcome measures are an assessment of safety and tolerability, pharmacokinetics and pharmacodynamics. Secondary endpoints include duration of response, progression free and overall survival. Tumor assessment is based on International Myeloma Working Group (IMWG) Response Criteria.

As of the November 10, 2021 data cut-off date, 37 patients have been treated in 10 cohorts with fixed doses ranging from 5 to 2860 µg/week or a step dosing regimen of 1620 µg priming dose followed by a 3240 µg/week target dose. Premedication to minimize CRS includes dexamethasone and other standard therapies. Enrolled patients had a median of 7 prior therapies. The most frequent treatment-emergent adverse events (TEAEs) occurring in greater than 20% were anemia, 17 patients (46%), fatigue, 12 patients (32%), and transient CRS, 9 patients (24%), No grade 3 or higher CRS was reported and one dose limiting toxicity (DLT) was reported, grade 4 AST, which resolved. Maximum tolerated dose has not been reached.

Clinical benefit was observed in the patients receiving higher doses. In 8 disease evaluable patients enrolled at 2150 µg/week an ORR of 63% was reported (5/8 patients) consisting of 1 stringent CR, 1 VGPR, and 3 PRs. including 1 patient with prior BCMA-targeting therapy exposure. The disease control rate, (DCR), was 88% based on 7/8 patients. For the 2860 µg/week cohort consisting of 5 evaluable patients, the ORR was 2/5 (40%) including a second stringent CR, with a DCR of 60%. As of the data cutoff, all responders remained on study treatment.

HPN217 demonstrated a dose proportional increase in Cmax and AUC with a median serum half-life of 74 hours (range of 38 – 197 hours), confirming half-life extension. Half-life, clearance rate, and volume of distribution were dose-independent, suggesting linear PK kinetics. Pharmacodynamic analysis shows a dose-dependent, transient increase in serum cytokines and chemokines (IL-6, IL-8, IL-10, TNFα).

Patients continue to be enrolled in the escalation phase of the trial, with a goal to identify a recommended Phase 2 dose for an expansion phase. The expansion phase of the trial will further evaluate the safety and activity of HPN217 in patients with R/R MM. This trial is titled, “A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM”. For additional information about the trial, please visit www.clinicaltrials.gov using the identifier NCT04184050.

Preclinical Data for HPN217 Presented at ASH

The poster titled “The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma” showcased translational studies to examine factors that may impact the therapeutic efficacy of HPN217. These factors include the target BCMA, in membrane-bound or soluble form, and concomitant or combination therapeutics such as gamma secretase inhibitor (GSI) and dexamethasone.

Preclinical data from this presentation for HPN217 demonstrated:

 

   

In a patient derived cell culture system, HPN217 was able to mediate multiple myeloma cell killing by autologous T cells in 80% of the cultures

 

   

Presence of dexamethasone appeared to have limited effect on the anti-tumor activity of HPN217-redirected T cells

 

   

GSI increased the expression of BCMA on multiple myeloma cells and enhanced the effect of HPN217

Preclinical evaluation of HPN217 in combination with approved and experimental multiple myeloma therapeutics is ongoing

 

2


Conference Call and Webcast Details

Harpoon’s management will host a webcast and conference call on Monday, December 13, 2021 at time 4:30 p.m. ET / 1:30 p.m. PT to review the data presented at ASH and provide an update on other pipeline programs. The live call may be accessed by dialing 866-951-6894 for domestic callers or 409-216-0624 for international callers using conference ID # 2760075.

A live webcast of the call will be available from the Events and Presentations section of the company’s website here and will be archived there shortly after the live event.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. The company’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “suggest,” “target,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the development and advancement of Harpoon Therapeutics’ platforms and product candidates, including progress, timing, scope, design and interim results of clinical trials, the association of interim clinical data and preclinical results with potential treatment outcomes, and other statements that are not historical fact. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, preliminary data and trends may not be predictive of future data or results, may not demonstrate safety or efficacy or lead to regulatory approval by the FDA or other regulatory agencies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the timing and results of unexpected litigation or other disputes, and the sufficiency of Harpoon Therapeutics’ cash resources. These and other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including under “Risk Factors” in Harpoon Therapeutics’ quarterly report on Form 10-Q for the quarter ended September 30, 2021 and future filings by Harpoon Therapeutics. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

 

3


Contacts:

Harpoon Therapeutics, Inc.

Georgia Erbez

Chief Financial Officer

650-443-7400

media@harpoontx.com

Westwicke ICR

Robert H. Uhl

Managing Director

858-356-5932

robert.uhl@westwicke.com

###

 

4

EX-99.2

Exhibit 99.2

 

LOGO

FOR IMMEDIATE RELEASE

Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms

 

   

Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase of ongoing trials

 

   

Encouraging profile of tolerability and activity seen at higher doses in both HPN217 and HPN328; low grade CRS manageable, no Grade 3 CRS reported

 

   

Interim data from the ongoing Phase 1/2 trial of HPN217 presented at the 2021 ASH Conference reported clinical activity at higher dose levels, including an overall response rate (ORR) of 63% and a disease control rate (DCR) of 88% in the HPN217 2150 µg/week cohort with a manageable safety profile

 

   

In the ongoing Phase 1/2 trial for HPN328, 3 out of 4 patients with small cell lung cancer (SCLC) in the two highest dose cohorts tested to date, experienced target lesion (TL) reduction , with one patient achieving a confirmed partial response (PR) with a 53% TL reduction

 

   

Discovery pipeline continues to advance, with an IND for HPN601, Harpoon’s first ProTriTAC targeting EpCAM, expected in the second half of 2022

 

   

Management to host webcast and conference call to review the interim data presented at ASH and provide a pipeline update today at 4:30 p.m.ET / 1:30 p.m. PT

SOUTH SAN FRANCISCO, Calif., December 13, 2021 - Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline update on its programs, including the interim data presented from the ongoing dose-escalation portion of the Phase 1/2 trial for HPN217 in patients with relapsed/refractory multiple myeloma (R/R MM) at the 63rd American Society for Hematology (ASH) Annual Meeting and Exposition. Harpoon has four product candidates in clinical trials that are based on its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s own immune cells to kill tumor cells.

“We are focused on advancing our clinical programs in 2022 and are pleased to see the HPN217 and HPN328 programs showing clinical activity at well tolerated dose levels, indicating a threshold effect.” stated Julie Eastland, President and CEO, Harpoon Therapeutics. “We look forward to the initiation of expansion cohorts to learn more about these promising TriTAC programs while building our future clinical pipeline with our first ProTriTAC candidate, HPN601 targeting EpCAM, currently in IND-enabling studies.”

“The interim clinical data from the escalation portion of the HPN217 trial shows robust anti-myeloma activity that is encouraging,” said Natalie Sacks, M.D., Chief Medical Officer of Harpoon. “In addition, we are observing tumor shrinkage in small lung cancer patients in the HPN328 trial, and we are excited to see validation of the TriTAC platform in both solid tumors and hematologic malignancies. We continue to investigate the performance of our novel technology in multiple indications and are encouraged by the signs of clinical activity and manageable tolerability profiles.”


Dose escalation for HPN217 (BCMA TriTAC) Phase 1/2 clinical trial Ongoing

Relapsed/refractory multiple myeloma patients (N=37) have been treated across 9 fixed dose cohorts of 5 to 2860 µg/week, and 1 step dose cohort of 1620 (priming) and 3240 (target) µg/week reflecting rapid dose expansion since the trial began. HPN217 has been well tolerated, with one DLT, Grade 4 AST which resolved, as of the November 10, 2021 data cutoff date.

The ASH poster presentation, included the following observations:

 

   

Encouraging clinical activity in higher dose cohorts including a 63% ORR and 88% DCR reported in the 2150 µg/week cohort with 8 disease evaluable patients with R/R MM, including one minimal residual disease (MRD) negative, stringent CR.

 

   

HPN217 shows tolerable safety profile with cytokine release syndrome (all Grade 1 or 2) observed in 9 of 37 patients (24%)

 

   

Patient enrollment and dose escalation is ongoing to define the RP2D and MTD

 

   

Introduction of step dose regimens has allowed for the administration of higher target doses.

Dose escalation for HPN328 (DLL3 TriTAC) Phase 1/2 clinical trial making rapid progress. Fifteen patients have been enrolled in dose cohorts ranging from 15 µg to 7200 µg per week in both fixed and step dose cohorts administered once weekly by intravenous infusion. Fifteen patients with a median of 2 lines (range 1 to 5) of prior therapy have been enrolled and eligible patients include small cell lung cancer patients who have relapsed after platinum chemotherapy and patients with other malignancies with high grade neuroendocrine tumors associated with DLL3 expression. HPN328 has been well tolerated with Grade 1-2 CRS reported in 33% of patients, no DLTs observed and MTD has not been reached. Among four patients with small cell lung cancer receiving the two highest doses tested to date, 1215 µg fixed dose and 3600-7200 µg step dose, three had target lesion reduction, including 1 confirmed RECIST partial response. The patient with a cPR experienced a target lesion reduction of 53% at week 10. Presentation of initial interim clinical data is planned for 2022.

IND-enabling studies for HPN601 (EpCAM ProTriTAC) are progressing as planned. HPN601 is the first conditionally active T cell engager based on the ProTriTAC platform. EpCAM is expressed in a broad range of solid tumors, including gastrointestinal cancers, potentially enabling HPN601 to address multiple indications with high unmet medical need. By the end of 2022, an IND submission for HPN601 is expected as well as identification of a second IND candidate from the ProTriTAC platform.

Harpoon’s T cell engager platforms, TriTAC, ProTriTAC, and TriTAC XR, are designed to mitigate different target toxicities across a range of disease indications, including solid and hematologic malignancies.

Next generation T cell engager platforms advancing. Harpoon continues to discover new technologies to improve the therapeutic application of T cell engagers. We recently introduced the TriTAC XR platform, which is designed to minimize on-target cytokine release syndrome. Nomination of an IND candidate from the TriTAC XR platform is also expected by the end of 2022.

Conference Call and Webcast Today

Harpoon’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT on Monday, December 13, 2021 to review the data presented at ASH and provide an update on its other pipeline programs. The live call may be accessed by dialing 866-951-6894 for domestic callers or 409-216-0624 for international callers and using conference ID # 2760075.

A live webcast of the call will be available from the Events and Presentations section of the company’s website at https://ir.harpoontx.com/events-and-presentations and will be archived there shortly after the live event.


About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. Harpoon has also developed a proprietary ProTriTAC platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. The company’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “potential,” “target,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the development and advancement of Harpoon Therapeutics’ platforms and product candidates, including progress, timing, scope, design and interim results of clinical trials, ability of TriTAC-XR T cell engager platform to mitigate toxicities, such as cytokine release syndrome, the candidates safety and tolerability profile, the use of T cell engagers for the treatment of non-oncology diseases in addition to solid tumors and hematologic malignancies, and other statements that are not historical fact. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, preliminary data and trends may not be predictive of future data or results, may not demonstrate safety or efficacy or lead to regulatory approval by the FDA or other regulatory agencies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the timing and results of unexpected litigation or other disputes, and the sufficiency of Harpoon Therapeutics’ cash resources. These and other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including under “Risk Factors” in Harpoon Therapeutics’ quarterly report on Form 10-Q for the quarter ended September 30, 2021 and future filings by Harpoon Therapeutics. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts:

Harpoon Therapeutics, Inc.

Georgia Erbez

Chief Financial Officer

650-443-7400

media@harpoontx.com


ICR Westwicke

Robert H. Uhl

Managing Director

858-356-5932

robert.uhl@westwicke.com

EX-99.3

Slide 1

Advancing T Cell Engager Immunotherapies DECEMBER 13, 2021 Exhibit 99.3


Slide 2

This presentation and accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this presentation. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this presentation and accompanying oral commentary include, but are not limited to, statements about the progress, timing, scope, design and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of platforms and product candidates, and the timing of development milestones for platforms and product candidates and future business, strategy and financial performance. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials, the risk that trials may be delayed and may not have satisfactory outcomes, and unexpected litigation or other disputes that impede clinical trial progress. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this presentation and accompanying oral commentary are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.   Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Harpoon’s own internal estimates and research. While Harpoon believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of Harpoon’s internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research. Forward Looking Statements


Slide 3

Presentation Agenda for Today Corporate Overview – Julie Eastland, President and CEO Clinical Pipeline Update – Natalie Sacks, M.D., CMO HPN217 (BCMA) HPN328 (DLL3) HPN536 (Mesothelin) ProTriTAC Scientific Update – Holger Wesche, Ph.D., CSO Program Status Summary and Conclusions – Julie Eastland


Slide 4

Corporate Overview


Slide 5

Clinical-Stage Immuno-Oncology Company Advancing a Novel Portfolio of T Cell Engagers Redirecting T Cells to Become Cancer Killers Strong Capabilities Broad Pipeline in Immuno-Oncology Novel T Cell Engaging Platforms Deep expertise in oncology, T cell engagement, and protein engineering Well-positioned financially $154.2M in cash & equivalents1 Strong patent protection across platforms and programs 3 technologies allowing for “off-the-shelf” T cell therapies Each designed with a distinct approach and profile TriTAC® (Tri-specific T cell activating construct) ProTriTAC (Prodrug activation in tumor micro-environment) TriTAC-XR (Extended-release with slow activation in circulation) 4 clinical-stage TriTACs across 7+ indications Programs directed against clinically validated targets Platform properties clinically validated Evidence of clinical benefit Advancing lead ProTriTAC™ candidate targeting EpCAM (IND-enabling) (1) As of 09/30/21


Slide 6

TriTAC Oncology ProTriTAC Oncology TriTAC-XR Oncology/ Non-Oncology Program Stage of Development Preclinical Phase 1 Phase 2 HPN328 (DLL3) Small Cell Lung Cancer & Other Tumors HPN2171 (BCMA) Multiple Myeloma HPN424 (PSMA) Prostate Cancer HPN536 (MSLN) Ovarian, Pancreatic & Other Solid Tumors HPN601 (EpCAM) Multiple Solid Tumors Phase 3 Broad Pipeline of Immuno-Oncology Programs Four Clinical Stage TriTAC Programs, Three Distinct TCE Platforms TriTAC Indications Discovery ProTriTAC TriTAC-XR (1) AbbVie retains option to worldwide exclusive rights


Slide 7

HPN217: TriTAC Targeting BCMA


Slide 8

HPN217-3001 Phase 1/2 Trial Design Relapsed/Refractory Multiple Myeloma *International Myeloma Working Group Uniform Response Criteria For Multiple Myeloma and Minimal Residual Disease Assessment in Multiple Myeloma  Target Population is R/R MM Disease progressing at time of study entry At least 3 prior therapies, including proteasome inhibitor, immunomodulatory drug (IMiD), and an anti-CD38 antibody Prior exposure to BCMA-targeting agents permitted in escalation phase Dosing & Administration Administered weekly by 1-hour IV infusion Current status as of Nov 10, 2021 data cutoff date 37 patients enrolled Dose cohorts range from 5-3240 µg/week Dose Escalation: Single patient Fixed Dose Escalation: 3 + 3 (3 – 6 pts per dose level) Part 1 – Dose Escalation Patients treated at MTD or RP2D MTD or RP2D Step Dose Escalation: 3 + 3 (3 – 6 pts per dose level) ³ Gr 2 adverse event Part 2 – Dose Expansion


Slide 9

HPN217 Rapid Escalation and Implementation of Step Dosing To Obtain Higher Exposures Dose Level (µg/week) N 5 1 15 1 30 2 90 1 270 2 810 4 1620 6 2150 11 2860 6 1620 (priming)→3240 (target) 3 Total 37 Dose Escalation Steps Highest target doses evaluated to-date: Fixed dose: 2860 µg Step dose: 1620 µg (priming) à 3240 µg (target) Data as of November 10, 2021


Slide 10

HPN217 Patient Baseline Characteristics: Heavily Pretreated R/R Multiple Myeloma Population Baseline Characteristics Total N = 37 Age (yr), Median (range) 71 (38 – 78) Duration of Disease (yr), Median (range) 8 (1 – 20) Prior Transplantation, N (%) 28 (76%) Prior Systemic Therapies, Median (range) 7 (2 – 16) Best Response To Most Recent Regimen PRIOR to Trial Enrollment N (%) Complete Response 1 (3%) Very Good Partial Response 4 (11%) Partial Response 5 (14%) Minimal Response 1 (3%) Stable Disease 10 (27%) Progressive Disease 12 (32%) Missing 4 (11%) Baseline Characteristics and Demographics Prior Systemic Therapies Therapeutic Class and Agents Total N = 37, N (%) Proteasome Inhibitor  Bortezomib 34 (92%) Carfilzomib 30 (81%) Ixazomib 10 (27%) Anti-CD38 Daratumumab 33 (89%) Isatuximab 3 (8%) IMiD Lenalidomide 34 (92%) Pomalidomide 31 (84%) Thalidomide 11 (30%) BCMA-Targeted Therapy Belantamab Mafodotin 6 (16%) SEA-BCMA 2 (5%) Bispecific TCE 1 (3%) CAR T-Cell Therapy 1 (3%) Data as of November 10, 2021 Prior to trial enrollment, 32% of patients had progressive disease as best response to most recent regimen 24% of patients received at least 1 prior BCMA-targeted therapy


Slide 11

Reported Adverse Events HPN217 Has Manageable Safety Profile  Event Grade 1 or Grade 2 ≥ Grade 3 All Grades (N=37) Hematological Adverse Events* Anemia 3 (8%) 14 (38%) 17 (46%) Non-Hematological Adverse Events* Fatigue 11 (30%) 1 (3%) 12 (32%) Aspartate Aminotransferase Increase 2 (5%) 5 (14%) 7 (19%) Cough 7 (19%) 0 (0%) 7 (19%) Alanine Aminotransferase Increase 3 (8%) 3 (8%) 6 (16%) Epistaxis 6 (16%) 0 (0%) 6 (16%) Headache 6 (16%) 0 (0%) 6 (16%) Arthralgia 5 (14%) 1 (3%) 6 (16%) Nausea 6 (16%) 0 (0%) 6 (16%) Diarrhea 6 (16%) 0 (0%) 6 (16%) Dyspnea 5 (14%) 1 (3%) 6 (16%) Common Adverse Events Per Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Grading, >15% frequency *Common AEs per CTCAE V5.0 grading Most common (>20%) AEs include anemia, fatigue, and cytokine release syndrome (CRS) One dose limiting toxicity (DLT) reported Grade 4 AST, resolved 22% of patients had at least 1 event of transaminitis; majority of events were observed at first dose, all were transient, with no clinical sequalae MTD not reached Data as of November 10, 2021


Slide 12

HPN217 Adverse Events: Focus on CRS No Grade 3 CRS Events Reported to Date Event 5/15/30/90/270 µg/wk (N=7) 810 µg/wk (N=4) 1620 µg/wk (N=6) 2150 µg/wk (N=11) 2860 µg/wk (N=6) 1620→3240 µg/wk (N=3) Total (N=37) CRS (Grade 1 or Grade 2) 0 (0%) 0 (0%) 1 (17%) 6 (55%) 2 (33%) 0 (0%) 9 (24%) CRS Grade 1* 0 (0%) 0 (0%) 1 (17%) 4 (36%) 1 (17%) 0 (0%) 6 (16%) CRS Grade 2* 0 (0%) 0 (0%) 0 (0%) 2 (18%) 1 (17%) 0 (0%) 3 (8%) IRR 0 (0%) 1 (25%) 0 (0%) 1 (9%) 0 (0%) 0 (0%) 2 (5%) Pyrexia 0 (0%) 1 (25%) 1 (17%) 6 (55%) 2 (33%) 0 (0%) 10 (27%) Hypotension 0 (0%) 0 (0%) 0 (0%) 4 (36%) 1 (17%) 0 (0%) 5 (14%) Cytokine Release Syndrome and Infusion Related Reactions CRS Grade 1/2 : 9 patients (24%) No Grade 3 CRS reported One patient in 2860 µg/week cohort received tocilizumab due to Grade 2 CRS on first dose No ASTCT-defined ICANS reported *Grading per ASTCT 2019 criteria Data as of November 10, 2021


Slide 13

HPN217 on Treatment Activity Emerging in Higher Dose Cohorts Time on Treatment for All Patients Treated Data as of November 10, 2021 IMWG assessments obtained every six weeks 5 15 30 90 270 810 1620 2150 2860 3240


Slide 14

HPN217 IMWG Responses Threshold Effect: Responses obtained at higher doses Data as of November 10, 2021 ORR* (PR and better) DCR** (SD and better) Median Time on Treatment (wks) 5 – 810 µg/week 0/11 (0%) 4/11 (36%) 7 (3-25) 1620 µg/week 0/6 (0%) 3/6 (50%) 8 (2-17) 2150 µg/week 5/8 (63%) 7/8 (88%) 12 (1-31+) 2860 µg/week 2/5 (40%) 3/5 (60%) 4 (1-7+) * ORR = overall response rate ** DCR = disease control rate +=median will change with additional follow-up Overall Response and Disease Control Rates Disease-evaluable patients shown: Responses are measured by International Myeloma Working Group Uniform Response Criteria For Multiple Myeloma and Minimal Residual Disease Assessment in Multiple Myeloma  *includes confirmed and unconfirmed responses Figure 4. Overall Response Rate Overall Response Rate* In 8 disease-evaluable patients enrolled at 2150 µg/wk: one stringent CR one VGPR three PRs observed, including patient with prior BCMA-targeting therapy exposure 2 patients with stringent CR are MRD negative as assessed by next generation flow cytometry All responders remain on study treatment


Slide 15

Signs of HPN217 Accumulation After Multiple Doses Linear PK profile: dose-proportional increase in Cmax and AUC, dose-independent clearance and volume of distribution Median half-life (T1/2) is 74 hours Evidence of HPN217 accumulation: First dose vs sixth dose ~1.5 – 2-fold increase in Cmax and AUC ~2.0 – 3-fold increase in Clast Pharmacokinetics Support Less Frequent Dosing Data as of November 10, 2021


Slide 16

Summary HPN217 Manageable Safety Profile and Active at Doses > 2150 µg/week HPN217 is generally well tolerated Transient low-grade CRS in 24% of patients, no Grade 3 reported to date MTD has not been reached one DLT of Grade 4 AST, resolved HPN217 is active 7 of 8 disease evaluable patients in the 2150 µg/week cohort demonstrated clinical benefit 63% ORR and 88% DCR observed in the 2150 µg/week cohort Responders include 1 patient with prior orvacabtagene autoleucel (JCARH125) treatment Next steps Continue dose escalation with step dosing to define the RP2D Explore less frequent dosing schedule, in parallel Define target population for expansion phase Data as of November 10, 2021


Slide 17

HPN328: TriTAC Targeting DLL3


Slide 18

HPN328 Phase 1/2 Trial Design An Open-Label, Multi-Center, Dose Escalation / Expansion, Safety & PK Study Target population Small cell lung cancer relapsed after platinum chemotherapy Other malignancies with high grade neuroendocrine features R/R to standard of care (SOC) or no SOC available Trial objectives Assess safety and tolerability at increasing dose levels PK and pharmacodynamic data Evaluate preliminary anti-tumor activity Dosing and administration Weekly IV infusion starting at 15µg Status 15 patients enrolled Dose escalation on-going Dose Escalation: Single patient fixed dosing Dose Escalation: 3 + 3 (3 – 6 pts per cohort) Step dosing implemented at this point Part 1 – Dose Escalation Part 2 – Dose Expansion Up to 27 patients with relapsed SCLC at the recommended phase 2 dose Simon 2-Stage design ³ Gr 2 AE related or suspected related to HPN328 MTD or RP2D


Slide 19

HPN328: Dose Cohorts 480-Fold Escalation Accomplished Data as of December 2, 2021 Dose Level (µg/week) n 15 1 45 1 135 1 405 3 1215 4 3600 1 3600 (priming)→7200 (target) 4 Total 15


Slide 20

HPN328 Baseline Demographics 93% of Patients Had Prior Anti-PD-1/PD-L1 Treatment *Other NET: Colorectal, Retroperitoneal, Pancreatic, Thymic Data as of December 2, 2021 Baseline Characteristics Total N = 15 Age (yr), Median (range) 61 (43 – 73) ECOG performance status 0-1, n (%) 15 (100) Brain / Liver metastases, n (%) 3 (20) / 8 (53.3) Disease n (%) Small Cell Lung Cancer 9 (60) Neuroendocrine Prostate Cancer 2 (13.3) Other Neuroendocrine Tumor* 4 (26.6) Prior Lines of Therapy n (%) 1 6 (40) 2 3 (20) ≥3 6 (40) Median (range) 2 (1-5) Prior anti-PD-1/PD-L1 treatment 14 (93.3)


Slide 21

No dose-limiting toxicities observed Maximum tolerated dose not reached CRS events: 5 of 15 patients experienced CRS (G1-2) All CRS events were managed with standard medications and resolved within hours When CRS occurred, it typically followed the first dose and did not recur on subsequent dosing Transaminitis: 3 of 15 patients experienced transaminitis (G1-2); transient and asymptomatic When transaminitis occurred, it typically followed the first dose, resolved to baseline within 2-3 days and did not recur on subsequent dosing No patients discontinued due to adverse events HPN328: Safety and Tolerability No Grade 3 CRS Observed to Date Data as of December 2, 2021


Slide 22

HPN328 Time on Treatment 3600 3600 3600 uPR -38% TL chg (week 9) Confirmed PR -53% TL chg (week 9) -21% TL chg (Week 9) -27% TL chg (Week 9) Dose Increase SCLC Prior PD1/L1 inhibitor Ongoing NEPC NET Other * % Target Lesion Reduction from Baseline -X% Objective Response (RECIST v1.1) CR, PR Dose (μg/week) / (# of Prior Txs) NET other: Retroperitoneal, Colorectal, Pancreatic, Thymus Data as of December 2, 2021


Slide 23

HPN328 SCLC patients Anti-tumor Activity at Higher Doses, Including Confirmed PR At doses of ≥1215μg/wk: 3/4 SCLC patients had target lesion (TL) reductions Dose (μg/week) * * * * * On study treatment aRECIST 1.1 Criteria: -Partial Response: 30% or greater TL reduction -Progressive Disease: 20% increase -30%a 20%a Data as of December 2, 2021


Slide 24

61-year-old female Diagnosed in January 2021 with extensive SCLC Location of metastases: TLs: lung, liver x2, lymph nodes x2 Non-TLs: lung x2, liver Prior systemic treatment: carboplatin etoposide+atezolizumab Time on most recent prior systemic treatment: 20.1 weeks Upon study entry, stable disease as best response to most recent prior systemic treatment Data as of December 2, 2021 HPN328 Patient Case One: SCLC 53% Reduction in Sum of Target Lesion Diameters at Week 10 Confirmed PR Patient History Results Initiated HPN328 at 1215μg/week Increased dose of HPN328 to 3600μg/week starting C3D15 (Week 8) Confirmed PR at week 10 Remains on HPN328 treatment beyond 17 weeks


Slide 25

Pre-Treatment Week 6 Post-Treatment Week 10 Post-Treatment 38% reduction at wk 6 53% reduction at wk 10 HPN328 Patient Case One: SCLC 53% Reduction in Sum of Target Lesion Diameters at Week 10 Confirmed PR Lymph Node Lung Liver Data as of December 2, 2021


Slide 26

67-year-old male Diagnosed in April 2020 with extensive SCLC Location of metastases TLs: liver x2, lymph nodes x2 Non-TLs: liver, lymph nodes x2, spleen, bone, brain Prior systemic treatment Carboplatin + etoposide + toripalimab (anti-PD1) (4 cycles – clinical trial) Cisplatin + etoposide (2 cycles) Lurbinectedin Time on most recent prior systemic treatment 10.9 weeks Upon study entry, partial response as best response to most recent prior systemic treatment Data as of December 2, 2021 HPN328 Patient Case Two: SCLC 27% Reduction in Sum of Target Lesion Diameters at Week 9 Baseline Week 9 Response in peri-portal lymph node Patient History Results HPN328 3600 à 7200 μg/week Week 9: 27% reduction in sum of target lesion diameters Responses seen primarily in lymph nodes Liver metastases stable Reports symptoms improved Remains on HPN328 treatment beyond 10 weeks


Slide 27

HPN328 Summary and Next Steps HPN328 is well-tolerated No Grade 3 CRS to date Grade 1-2 CRS in 33% of patients No DLTs MTD not yet identified HPN328 activity signal at doses ≥1215 μg/week: Small Cell Lung Cancer 3 out of 4 patients with target lesion shrinkage, including 1 confirmed RECIST partial response Deepening of responses observed over time Responders ongoing Next steps Continue step dose escalation Selection of dose and target population for first expansion cohort Data as of December 2, 2021


Slide 28

HPN536 Phase 1/2a Trial Design and Status Mesothelin-Targeting TriTAC Enrolling Late-stage Ovarian, Pancreatic and Mesothelioma Cancer Patients HPN536 escalation study ongoing in multiple indications 83 patients enrolled Target doses up to 3600 ng/kg achieved Now enrolling cohort to evaluate target dose of 7200 ng/kg HPN536 well-tolerated, profile may permit significant escalation No new DLTs beyond 2 previously reported MTD not reached Next steps Rapid escalation to identify RP2D with step-dose now deployed Selection of target population(s) for expansion phase Dose Escalation: single patient Fixed Dose Escalation: 3 + 3 (3 – 6 pts per dose level) Part 1 – Dose Escalation 3 cohorts (Ovarian, Pancreatic and Mesothelioma) ~20 patients per cohort (Simon 2-Stage design) MTD or recommended Phase 2 dose Step Dosing Dose Escalation: 3 + 3 (3 – 6 pts per dose level) ³ Gr 2 study drug related toxicity Part 2 – Dose Expansion Status Data as of December 2, 2021


Slide 29

Clinical Summary Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase Learnings from earlier programs have enabled rapid dose escalation and effective CRS management Encouraging profile of tolerability and activity seen at higher doses Escalation ongoing to obtain higher exposures and identify RP2D Exploring expedited paths forward in robust patient populations These data validate the TriTAC platform in both solid tumors and hematologic malignancies


Slide 30

T Cell Engager Platforms


Slide 31

T cell Engager Platforms Are Optimized to Address Target-Specific Safety Concerns TriTAC ProTriTAC TriTAC-XR Prodrug Active αALB αTarget αCD3 Finalizing platform validation Maximize systemic exposure while minimizing CRS Heme malignancies and solid tumors with potential expansion to non-oncology Four, active clinical-stage programs Least complex platform Solid tumors and heme malignancies with limited on-target tox concerns Lead program in IND-enabling studies Minimize systemic exposure by acting locally at disease site Primarily solid tumors Active Prodrug protease linker masking moiety αTarget αALB αCD3 Active Slow activation in circulation Short-lived TEMPORAL CONTROL Minimize on-target CRS SPATIAL CONTROL Minimize on-target tissue tox CONSTITUTIVELY ACTIVE Minimize off-target toxicities (CRS) Long-lived Activation in tumor micro-environment


Slide 32

Platforms Designed To Address T Cell Engager Associated Toxicities Prodrug administered systemically Active drug formed through local activation at tumor site Active drug has short half-life Prodrug administered systemically Active drug formed systemically, but in a slow, controlled fashion Active drug has long half-life Active drug administered directly Ideal for targets with minimal expression in normal tissues >200x active active active prodrug prodrug Spatial Control Temporal Control TriTAC ProTriTAC TriTAC-XR Constitutive Activity


Slide 33

Harpoon’s First ProTriTAC HPN601 Is Designed to Target EpCAM, Potentially Addressing Large Unmet Medical Need Tumor EpCAM Expression1 (% moderate/high expression by IHC) HPN601 Population2 (estimated annual incidence in USA) Prostate 89 171,000 NSCLC 74 147,000 Breast 46 128,000 Colon 94 99,000 Endometrial 88 58,000 Thyroid 87 46,000 SCLC 75 22,000 Gastric 74 21,000 Ovarian 73 16,000 Esophageal 65 12,000 Neuroendocrine 88 11,000 Gallbladder 66 8,000 Total 729,000 1Based on Spizzo et al., J Clin Pathol, 2011. 2Estimated annual incidence in US, rounded to the nearest 1,000, based on the American Cancer Society’s (ACS) publication, Cancer Facts & Figures 2020, multiplied by the percentage of moderate and high EpCAM expression. The neuroendocrine tumor annual incidence taken from ASCO Cancer.net. Exemplary IHC figures adapted from proteinatlas. EpCAM’s broad tumor expression enables a balance of Fast-to-market vs. large indications PD-1/PD-L1 sensitive vs. insensitive indications Anticipate IND by year end 2022 Colorectal NSCLC


Slide 34

Evidence of TI Expansion for EpCAM-Targeting HPN601: Harpoon’s First ProTriTAC Clinical Candidate Better Efficacy in Rodents Better Safety in Non-Human Primates Control TriTAC ProTriTAC (HPN601) Both TriTAC and ProTriTAC dosed at 100 µg/kg Peak Cytokine Levels Both TriTAC and ProTriTAC dosed at 30 µg/kg Established Tumor Xenograft Model TriTAC ProTriTAC (HPN601) TI expansion also supported with combined mouse efficacy/toxicity models1 1. Lin et al., SITC 2020 presentation


Slide 35

Harpoon Is Committed To Developing Next-Generation T Cell Engagers and Expanding Their Therapeutic Applications Solid tumor Heme Utility TriTAC ✓ ✓ Most robust platform minimizing off-target toxicities ProTriTAC ✓ Spatial control of activity to address on-target tissue damage TriTAC-XR ✓ ✓ Temporal control of activity to address on-target CRS Three T cell engager platforms for different applications Upcoming platform milestones by the end of 2022: ProTriTAC IND for lead ProTriTAC HPN601 (targeting EpCAM) TriTAC-XR Nomination of IND candidates


Slide 36

Program Status Summary and Conclusions


Slide 37

Summary and Conclusions Clinical progress continues HPN328 and HPN217 rapid dose escalation is driving early clinical activity across a spectrum of heavily pre-treated patients Dose levels reaching thresholds showing activity 2022 will focus on advancing our clinical programs that are demonstrating the differentiating features of our TriTAC technology Advancing our platform technologies New programs moving toward the clinical with our first ProTriTAC platform candidate, HPN601 Continual platform innovations to address a broader range of targets such as TriTAC-XR to focus on the development of targets across both solid and liquid tumors as well as non-oncology indications Future data updates and clinical development activity to be presented at medical and scientific meetings as data develops throughout 2022. An R&D Day for investors is being planned. Strong financial position with $154.2m cash (9/30/21) to fund clinical programs and operations


Slide 38

Advancing T Cell Engager Immunotherapies DECEMBER 13, 2021